AlphAIAlphAI — Financial news for AI agents
bdnews24.comOCT 242 min read$AMGN

Amgen drug paired with immunotherapy improves survival in lung cancer trial: report

Amgen's Imdelltra, combined with AstraZeneca's Imfinzi, showed a 58% reduction in death risk in a lung cancer trial. Median survival was 21.1 months vs. 12.7 months for Imfinzi alone. Amgen's chief medical officer called the results unprecedented. The drug's list price is $30,000 per cycle, with estimated sales over $2.5B by 2030. The trial involved 563 patients and was presented at a medical conference.

Original reporting
bdnews24.com
Published Oct 24, 2026, 3:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 24, 2026, 6:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Amgen drug paired with immunotherapy improves survival in lung cancer trial: report — source image
Source · bdnews24.com
Decision brief

The 30-second read

$AMGNBullishMed
01

Why it matters

The trial establishes a new standard of care for extensive‑stage small cell lung cancer, potentially reshaping treatment guidelines.

02

Market read

First disclosure of pivotal trial results that could drive significant revenue for Amgen and affect competitive dynamics for AstraZeneca.

03

What to watch

Regulatory approval timelines, reimbursement challenges, and competition from emerging CAR‑T therapies.

Relevance 7/10Novelty 8/10Timing: post‑meeting today

Background

The data were presented at the European Society for Medical Oncology meeting and published in the New England Journal of Medicine.

Company-level read

Ticker impact

$AMGNBullishHigh confidence
Context

Amgen's Imdelltra showed a 58% mortality reduction in a Phase 3 small cell lung cancer trial, the first public disclosure of these results.

Expected impact

upward pressure as investors price in potential $2.5B sales by 2030.

Evidence & confidence

First-time release of pivotal trial outcomes with strong efficacy and sizable revenue forecasts.

$AZNNeutralMedium confidence
Context

AstraZeneca's immunotherapy Imfinzi was the comparator in the same trial, showing lower survival versus the Amgen combo.

Expected impact

slight pressure as market may shift focus to the Amgen combo.

Evidence & confidence

Trial highlights Imfinzi's relative performance, but no direct negative news about AstraZeneca's broader portfolio.

Market effects

Sector

Strengthens the oncology/biotech sector, especially companies developing bispecific antibodies.

Regional

U.S. biotech stocks may see a rally, while European markets watch AstraZeneca's response.

Global

Potentially influences global cancer‑therapy pipelines and investor allocations to biotech ETFs.

Counterpoint

What could challenge this read

Investors may question the commercial viability given high treatment cost and modest absolute survival gain.

Key entities

  • Company
    Amgen

    Developer of Imdelltra, a bispecific antibody.

  • Company
    AstraZeneca

    Provider of Imfinzi, an immunotherapy checkpoint inhibitor.

  • Executive
    Paul Burton

    Chief Medical Officer at Amgen, quoted on trial significance.

Read at source← All news

StoryImdelltra plus Imfinzi cuts death risk by 58% in first‑line extensive‑stage small cell lung cancer

Also covered by

3 outlets

Related articles

OCT 24
$AZNHigh

AZ Combo Extends Lung Cancer Survival

AstraZeneca's Imfinzi and Amgen's Imdelltra combination therapy extended survival by eight months in advanced lung cancer patients, reducing death risk by 58% according to a trial. Side effects were manageable, with 1% experiencing neurological issues. AstraZeneca also reported positive bladder cancer data for Imfinzi plus Pfizer's Padcev. Both studies were presented at an oncology meeting in Madrid.

briefs.co2 min
OCT 24
$AZNHigh

AstraZeneca: Perioperative IMFINZI (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer

AstraZeneca's VOLGA Phase III trial showed that perioperative IMFINZI (durvalumab) plus neoadjuvant enfortumab vedotin reduced the risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer patients. The combination therapy demonstrated statistically significant improvements in event-free survival and overall survival compared to the standard of care. According to AstraZeneca, more than three quarters of patients were still alive two years after treatment.

finanznachrichten.de3 min
OCT 24
$AMGNMedAI 8/10

New Amgen drug combination shows survival gains in lung cancer trial

Amgen's Imdelltra, combined with AstraZeneca's Imfinzi, reduced mortality risk by 58% in a lung cancer trial. Imdelltra's US list price is around $300,000 per cycle. Analysts project annual revenues exceeding $2.5B by 2030. The drug is approved for extensive-stage small cell lung cancer, with 80% of trial patients alive at one year.

thenews.com.pk2 min
OCT 24
$AZNMedAI 8/10

Astrazeneca Reports Positive Results from Volga Phase Iii Trial of Perioperative Imfinzi Plus Neoadjuvant Enfortumab Vedotin in Muscle-Invasive Bladder Cancer

AstraZeneca's IMFINZI with neoadjuvant EV showed significant improvements in event-free and overall survival in muscle-invasive bladder cancer patients. The combination reduced the risk of disease progression by 49% and death by 42% compared to standard care. The FDA granted Priority Review for this treatment in September 2026. The VOLGA Phase III trial involved 695 patients across 182 centers in 25 countries.

marketscreener.com2 min
OCT 24
$AMGNHighAI 9/10

Amgen Announces IMDELLTRA in Combination with Imfinzi Reduces Risk of Death in First-Line Extensive Stage Small Cell Lung Cancer

Amgen reported Phase 3 trial results showing IMDELLTRA with AstraZeneca's IMFINZI reduced death risk by 58% in extensive stage small cell lung cancer. Median progression-free survival was 7.4 months vs. 1.9 months. Safety profiles were consistent with known data. Additional data reinforced sustained outcomes. The trial included 563 patients and was sponsored by Amgen with partial funding from AstraZeneca.

marketscreener.com2 min